AGX101 is a special kind of cancer medicine called an antibody-drug conjugate (ADC) given through a vein to help treat advanced solid tumors, which are hard lumps caused by cancer. This study is checking if AGX101 is safe and how well it works. People in the study will get the medicine every 3, 6, or 9 weeks and can continue until their disease worsens, they have bad side effects, or they choose to stop. After treatment, there will be a final visit and two follow-up calls within 90 days.
- Study Visits: Participants will have regular visits for treatment and follow-ups.
- Eligibility: Patients must have advanced cancer and be unable to have surgery, among other criteria.
- Risks: Possible side effects and need to meet certain health conditions to join.
To join, participants need to have certain types of cancer, must have tried other treatments, and be in good overall health. Some people, like those with certain infections or recent surgeries, can't participate. It's important to discuss with a doctor to see if this study is the right choice.